JB Chemicals & Pharmaceuticals Limited

rs,

ironment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company

60%

istent track record across multiple businesses 5 Brands among top 300 brands, contributing over 60% of domestic formulations revenues 40+ Regulated/semi-regulated markets of presence through dir

24%

Top 5 Global manufacturer of medicated/herbal lozenges representing a substantial opportunity 24% Growth in chronic therapies* in the domestic formulations business #2500 Strong India field fo

22%

cused segmentation 7 Multi-dosage formulation plants with key global approvals/ compliances **22% ROCE with consistent cash flow generation generating good returns * CAGR over FY20-FY22 (IQVIA

18.6%

4 Corporate Snapshot – Financial Overview Revenue (INR cr) PAT (INR cr) *Op EBITDA Margin (%) 18.6% 21.3% 1,643 1,775 15.4% 1,413 27.4% 25.0% 2,043 2,424 139 194 272 449 386 FY18 FY19

21.3%

porate Snapshot – Financial Overview Revenue (INR cr) PAT (INR cr) *Op EBITDA Margin (%) 18.6% 21.3% 1,643 1,775 15.4% 1,413 27.4% 25.0% 2,043 2,424 139 194 272 449 386 FY18 FY19 FY20

15.4%

ancial Overview Revenue (INR cr) PAT (INR cr) *Op EBITDA Margin (%) 18.6% 21.3% 1,643 1,775 15.4% 1,413 27.4% 25.0% 2,043 2,424 139 194 272 449 386 FY18 FY19 FY20 FY21 FY22 15% 10%

27.4%

w Revenue (INR cr) PAT (INR cr) *Op EBITDA Margin (%) 18.6% 21.3% 1,643 1,775 15.4% 1,413 27.4% 25.0% 2,043 2,424 139 194 272 449 386 FY18 FY19 FY20 FY21 FY22 15% 10% FY18 24% 1

25.0%

nue (INR cr) PAT (INR cr) *Op EBITDA Margin (%) 18.6% 21.3% 1,643 1,775 15.4% 1,413 27.4% 25.0% 2,043 2,424 139 194 272 449 386 FY18 FY19 FY20 FY21 FY22 15% 10% FY18 24% 13% FY1

15%

5 15.4% 1,413 27.4% 25.0% 2,043 2,424 139 194 272 449 386 FY18 FY19 FY20 FY21 FY22 15% 10% FY18 24% 13% FY19 42% 25% 29% 19% 22% 18% FY20 FY21 FY22 ROE (%) ROCE (%) Incr

10%

.4% 1,413 27.4% 25.0% 2,043 2,424 139 194 272 449 386 FY18 FY19 FY20 FY21 FY22 15% 10% FY18 24% 13% FY19 42% 25% 29% 19% 22% 18% FY20 FY21 FY22 ROE (%) ROCE (%) Increasin

13%

% 25.0% 2,043 2,424 139 194 272 449 386 FY18 FY19 FY20 FY21 FY22 15% 10% FY18 24% 13% FY19 42% 25% 29% 19% 22% 18% FY20 FY21 FY22 ROE (%) ROCE (%) Increasing Share of the D

Registered Office

1

Corporate Office

1

Registered Office

J.B. Chemicals & Pharmaceuticals Limited, CIN: L24390MH1976PLC019380 Neelam Centre, ‘B’ Wing, 4" Floor, Hind Cycle Road, Worli, Mumbai — 400030, T:+91 22 24822222

Corporate Office

J.B. Chemicals & Pharmaceuticals Limited, CIN: L24390MH1976PLC019380 Cnergy IT Park, Unit A, 8" Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai — 400025, T:+91 22 24395200/5500 www.jbpharma.com JB Pharma - Q1 FY23 Financial Results August 4, 2022 www.jbpharma.com jbpharma/ 1 Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management JB Chemicals & Pharmaceuticals Limited (“Company” or “JB Pharma” or “JB Chemicals & Pharmaceuticals Limited ”), which are expressed in good faith and in their opinion reasonable, including